1,3-dioxan-5-ylalkenoic acids
    11.
    发明授权
    1,3-dioxan-5-ylalkenoic acids 失效
    1,3-二恶烷-5-基链烯酸

    公开(公告)号:US5166377A

    公开(公告)日:1992-11-24

    申请号:US153928

    申请日:1988-02-09

    摘要: The invention concerns novel 4-phenyl-1,3-dioxan-5-ylalkenoic acid derivatives of the formula I having cis relative stereochemistry at positions 4 and 5 of the dioxane ring and wherein Ra and Rb are variously hydrogen, alkyl, halogenoalkyl, alkenyl, and optionally substituted aryl or arylalkyl, Rc is hydroxy, alkoxy or alkanesulphonamido, n is 1 or 2, A is ethylene or vinylene, Y is (2-5C)polymethylene optionally substituted by alkyl, and benzene ring B is optionally substituted phenyl, or, when Rc is hydroxy, a salt thereof. The acid derivatives antagonize one or more of the actions of thromboxane A.sub.2 (TXA.sub.2) and are expected to be of value in those disease conditions in which TXA.sub.2 is involved. The invention also provides pharmaceutical compositions containing an acid derivative of formula I, and processes for their chemical production.

    摘要翻译: 本发明涉及式I的4-苯基-1,3-二恶烷-5-基亚烯基酸衍生物,其在二恶烷环的4和5位具有顺式相对立体化学,其中Ra和Rb分别为氢,烷基,卤代烷基,烯基 和任选取代的芳基或芳基烷基,R c是羟基,烷氧基或烷基磺酰胺基,n是1或2,A是亚乙基或亚乙烯基,Y是任选被烷基取代的(2-5C)聚亚甲基,苯环B是任选取代的苯基, 或当Rc为羟基时,其盐。 酸衍生物拮抗血栓素A2(TXA2)的一种或多种作用,并且预期在涉及TXA2的那些疾病状况下具有价值。 本发明还提供含有式I酸衍生物的药物组合物及其化学生产方法。